Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Ruxolitinib in the real world: myelofibrosis

Aaron Gerds, MD, MS, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, discusses the real-world analysis of ruxolitinib treatment patterns and outcomes among patients with myelofibrosis (MF). Dr Gerds highlights how there continues to be a need for additional therapeutic options for MF. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.